3 completed, 1 not yet recruiting, 1 recruiting, 1 withdrawn. 6 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 3, Not yet recruiting 1, Recruiting 1, Withdrawn 1 |
| Phase 3 | 1 | Not yet recruiting 1 |
Follow Visual Acuity: new trials by email Literature Review of Visual Acuity trials Research Report on Visual Acuity
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Metric-Optimized Spectacle Prescriptions for Children With Down Syndrome Metric-optimized spectacles, Routine Clinical Spectacles - Refractive Error Correction, Visual Acuity | Phase 2 | Recruiting | Ohio State University | 24 | 2026-07-13 | 2026-07-20 |
| Evaluating Efficacy and Safety of Oral Melatonin in Acute Central Serous Chorioretinopathy melatonin 3mg, Placebo Drug - Central Serous Chorioretinopathy, Melatonin | Phase 2 / Phase 3 | Not yet recruiting | Mohsen Pourazizi | 48 | 2025-02-01 | 2025-02-05 |
| Clinical Investigation of Visual Acuity in Contact Lens Wearers After Instillation of Investigational Lubricating Eye Drops Blink® Tears eye drops in a multidose bottle, Preservative-free investigational lubricating eye drops in a Novelia® eyedropper - Visual Acuity | Phase 2 | Completed | Johnson & Johnson Vision Care, Inc. | 46 | 2023-04-06 | 2025-04-27 |
| Efficacy and Safety Study of CNTO 2476 in Participants With Visual Acuity Impairment Associated With Geographic Atrophy (GA) Secondary to Age Related Macular Degeneration (AMD) CNTO 2476 (6.0 * 10^4 cells), CNTO 2476 (3.0 * 10^5 cells) - Visual Acuity, Geographic Atrophy | Phase 2 | Withdrawn | Janssen Pharmaceutical K.K. | 2018-04-09 | 2025-02-03 | |
| Clinical Evaluation of Etafilcon A With Ketotifen etafilcon A with ketotifen, 1-Day ACUVUE - Visual Acuity | Phase 2 | Completed | Johnson & Johnson Vision Care, Inc. | 143 | 2017-12-06 | 2022-03-17 |
| A Study to Evaluate the Safety and Clinical Response of Subretinal Administration of CNTO 2476 in Participants With Geographic Atrophy CNTO 2476 3.0 x 10^5 cells, Subretinal Delivery System - Visual Acuity, Geographic Atrophy | Phase 2 | Completed | Janssen Research & Development, LLC | 21 | 2015-12-04 | 2025-04-29 |
Geographic Atrophy (2) · Macular Degeneration (2) · Central Serous Chorioretinopathy (1) · Down Syndrome (1)
Eye Diseases (3) · Retinal Diseases (3) · Retinal Degeneration (2) · Abnormalities, Multiple (1) · Chromosome Disorders (1) · Congenital Abnormalities (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Genetic Diseases, Inborn (1) · Intellectual Disability (1) · Nervous System Diseases (1) · Neurobehavioral Manifestations (1) · Neurologic Manifestations (1)
Johnson & Johnson Vision Care, Inc. (2) · Janssen Pharmaceutical K.K. (1) · Janssen Research & Development, LLC (1) · Mohsen Pourazizi (1) · Ohio State University (1)
United States (4)
Mohsen Pourazizi (1)
R01EY024590 (1)